Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?

Detalhes bibliográficos
Autor(a) principal: Uzun,Mehmet Ali
Data de Publicação: 2022
Outros Autores: Tilki,Metin, Gönültaş,Aylin, Aker,Fügen, Kayaoglu,Sevcan Alkan, Okuyan,Gülten Çiçek
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000500664
Resumo: SUMMARY OBJECTIVE: This study aimed to examine the prognostic effect of the tumor-stroma ratio, which has been shown to have prognostic value in various cancers, in patients with gallbladder cancer who have undergone curative resection. METHODS: The records of gallbladder cancer patients who underwent surgical treatment in our clinic between December 2005 and March 2021 were analyzed retrospectively. The hematoxylin and eosin-stained sections representing the tumors were evaluated under light microscopy to determine tumor-stroma ratio, and based on the results, <50% was defined as the stroma-rich and ≥50% as the stroma-poor groups. RESULTS: A total of 28 patients, including 20 females and 8 males, with a mean age of 64.6 years, were included in this study. Stroma-poor and stroma-rich tumors were detected in 15 and 13 patients, respectively. There was no statistically significant relationship identified between tumor-stroma ratio and advanced age, gender, serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen, incidental or nonincidental diagnosis, jaundice, adjacent organ or structure resection, tumor location, grades 1–2 or 3, T1/T2 or T3/T4, N0 or N1/N2, M stage, American Joint Committee on Cancer stage, lymphovascular invasion, and perineural invasion. The stroma-poor and stroma-rich groups had a 5-year survival rate of 30% and 19.2% and a median overall survival of 25.7 and 15.1 months, respectively, with no statistically significant difference between the groups (p=0.526). CONCLUSIONS: A low tumor-stroma ratio tended to be a poor prognostic factor in gallbladder cancer, although not to a statistically significant degree. This can be considered one of the preliminary studies, as further studies involving larger groups are needed.
id AMB-1_08107584d781fa7c440b537be0a3a1e7
oai_identifier_str oai:scielo:S0104-42302022000500664
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?Gallbladder neoplasmsPrognosisTumor microenvironmentSUMMARY OBJECTIVE: This study aimed to examine the prognostic effect of the tumor-stroma ratio, which has been shown to have prognostic value in various cancers, in patients with gallbladder cancer who have undergone curative resection. METHODS: The records of gallbladder cancer patients who underwent surgical treatment in our clinic between December 2005 and March 2021 were analyzed retrospectively. The hematoxylin and eosin-stained sections representing the tumors were evaluated under light microscopy to determine tumor-stroma ratio, and based on the results, <50% was defined as the stroma-rich and ≥50% as the stroma-poor groups. RESULTS: A total of 28 patients, including 20 females and 8 males, with a mean age of 64.6 years, were included in this study. Stroma-poor and stroma-rich tumors were detected in 15 and 13 patients, respectively. There was no statistically significant relationship identified between tumor-stroma ratio and advanced age, gender, serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen, incidental or nonincidental diagnosis, jaundice, adjacent organ or structure resection, tumor location, grades 1–2 or 3, T1/T2 or T3/T4, N0 or N1/N2, M stage, American Joint Committee on Cancer stage, lymphovascular invasion, and perineural invasion. The stroma-poor and stroma-rich groups had a 5-year survival rate of 30% and 19.2% and a median overall survival of 25.7 and 15.1 months, respectively, with no statistically significant difference between the groups (p=0.526). CONCLUSIONS: A low tumor-stroma ratio tended to be a poor prognostic factor in gallbladder cancer, although not to a statistically significant degree. This can be considered one of the preliminary studies, as further studies involving larger groups are needed.Associação Médica Brasileira2022-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000500664Revista da Associação Médica Brasileira v.68 n.5 2022reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20220037info:eu-repo/semantics/openAccessUzun,Mehmet AliTilki,MetinGönültaş,AylinAker,FügenKayaoglu,Sevcan AlkanOkuyan,Gülten Çiçekeng2022-09-13T00:00:00Zoai:scielo:S0104-42302022000500664Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2022-09-13T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
title Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
spellingShingle Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
Uzun,Mehmet Ali
Gallbladder neoplasms
Prognosis
Tumor microenvironment
title_short Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
title_full Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
title_fullStr Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
title_full_unstemmed Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
title_sort Is the tumor-stroma ratio a prognostic factor in gallbladder cancer?
author Uzun,Mehmet Ali
author_facet Uzun,Mehmet Ali
Tilki,Metin
Gönültaş,Aylin
Aker,Fügen
Kayaoglu,Sevcan Alkan
Okuyan,Gülten Çiçek
author_role author
author2 Tilki,Metin
Gönültaş,Aylin
Aker,Fügen
Kayaoglu,Sevcan Alkan
Okuyan,Gülten Çiçek
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Uzun,Mehmet Ali
Tilki,Metin
Gönültaş,Aylin
Aker,Fügen
Kayaoglu,Sevcan Alkan
Okuyan,Gülten Çiçek
dc.subject.por.fl_str_mv Gallbladder neoplasms
Prognosis
Tumor microenvironment
topic Gallbladder neoplasms
Prognosis
Tumor microenvironment
description SUMMARY OBJECTIVE: This study aimed to examine the prognostic effect of the tumor-stroma ratio, which has been shown to have prognostic value in various cancers, in patients with gallbladder cancer who have undergone curative resection. METHODS: The records of gallbladder cancer patients who underwent surgical treatment in our clinic between December 2005 and March 2021 were analyzed retrospectively. The hematoxylin and eosin-stained sections representing the tumors were evaluated under light microscopy to determine tumor-stroma ratio, and based on the results, <50% was defined as the stroma-rich and ≥50% as the stroma-poor groups. RESULTS: A total of 28 patients, including 20 females and 8 males, with a mean age of 64.6 years, were included in this study. Stroma-poor and stroma-rich tumors were detected in 15 and 13 patients, respectively. There was no statistically significant relationship identified between tumor-stroma ratio and advanced age, gender, serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen, incidental or nonincidental diagnosis, jaundice, adjacent organ or structure resection, tumor location, grades 1–2 or 3, T1/T2 or T3/T4, N0 or N1/N2, M stage, American Joint Committee on Cancer stage, lymphovascular invasion, and perineural invasion. The stroma-poor and stroma-rich groups had a 5-year survival rate of 30% and 19.2% and a median overall survival of 25.7 and 15.1 months, respectively, with no statistically significant difference between the groups (p=0.526). CONCLUSIONS: A low tumor-stroma ratio tended to be a poor prognostic factor in gallbladder cancer, although not to a statistically significant degree. This can be considered one of the preliminary studies, as further studies involving larger groups are needed.
publishDate 2022
dc.date.none.fl_str_mv 2022-05-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000500664
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000500664
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20220037
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.68 n.5 2022
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212837715083264